Payment overview · 2025
General Payments
$79.50
4 reported records · 3 companies
Healthcare provider profile · identity verified
Joseph T Hilgeman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DES PERES, MO · NPI 1407820145
Verified facts
What the public records show
CMS Open Payments records show Joseph T Hilgeman, MD received $79.50 in general payments during 2025 across 4 reported records.
Lilly USA, LLC accounted for 49.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.70 | 49.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.91 | 28.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.89 | 21.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.50 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 38 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
261 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1489 | 429 |
| Amlodipine Besylate | Amlodipine Besylate | 1301 | 356 |
| Losartan Potassium | Losartan Potassium | 707 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 702 | 179 |
| Alprazolam | Alprazolam | 559 | 139 |
| Omeprazole | Omeprazole | 477 | 145 |
| Tamsulosin Hcl | Tamsulosin Hcl | 437 | 132 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 399 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 396 | 127 |
| Lisinopril | Lisinopril | 360 | 100 |
| Potassium Chloride | Potassium Chloride | 315 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 312 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 310 | 88 |
| Finasteride | Finasteride | 306 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 302 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 283 | 83 |
| Gabapentin | Gabapentin | 280 | 85 |
| Simvastatin | Simvastatin | 265 | 71 |
| Eliquis | Apixaban | 261 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 260 | 64 |
| Tramadol Hcl | Tramadol Hcl | 246 | 79 |
| Sertraline Hcl | Sertraline Hcl | 233 | 59 |
| Metformin Hcl | Metformin Hcl | 230 | 65 |
| Fluoxetine Hcl | Fluoxetine Hcl | 222 | 62 |
| Furosemide | Furosemide | 215 | 70 |
| Trazodone Hcl | Trazodone Hcl | 204 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 77 |
| Lorazepam | Lorazepam | 179 | 38 |
| Prednisone | Prednisone | 175 | 91 |
| Atenolol | Atenolol | 161 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 59 |
| Montelukast Sodium | Montelukast Sodium | 154 | 46 |
| Irbesartan | Irbesartan | 143 | 38 |
| Glipizide | Glipizide | 132 | 41 |
| Donepezil Hcl | Donepezil Hcl | 129 | 32 |
| Allopurinol | Allopurinol | 125 | 35 |
| Meloxicam | Meloxicam | 125 | 38 |
| Bupropion Xl | Bupropion Hcl | 117 | 32 |
| Diazepam | Diazepam | 115 | 35 |
| Mirtazapine | Mirtazapine | 113 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 33 |
| Famotidine | Famotidine | 107 | 39 |
| Ibandronate Sodium | Ibandronate Sodium | 102 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 26 |
| Carvedilol | Carvedilol | 94 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 21 |
| Mounjaro | Tirzepatide | 90 | 13 |
| Synthroid | Levothyroxine Sodium | 87 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 20 |
| Temazepam | Temazepam | 83 | 18 |
| Xarelto | Rivaroxaban | 83 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 25 |
| Warfarin Sodium | Warfarin Sodium | 80 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 23 |
| Pregabalin | Pregabalin | 74 | 16 |
| Valacyclovir | Valacyclovir Hcl | 73 | 27 |
| Metformin Hcl Er | Metformin Hcl | 70 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 21 |
| Spironolactone | Spironolactone | 63 | 20 |
| Ozempic | Semaglutide | 61 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | 18 |
| Clonazepam | Clonazepam | 60 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 56 | 15 |
| Cephalexin | Cephalexin | 53 | 43 |
| Memantine Hcl | Memantine Hcl | 51 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 39 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 50 | 50 |
| Celecoxib | Celecoxib | 50 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 50 | 12 |
| Chlorthalidone | Chlorthalidone | 49 | 16 |
| Amoxicillin | Amoxicillin | 48 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | 13 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Torsemide | Torsemide | 47 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 13 |
| Glipizide Er | Glipizide | 44 | 14 |
| Januvia | Sitagliptin Phosphate | 44 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 13 |
| Colchicine | Colchicine | 43 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Glimepiride | Glimepiride | 42 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 38 | 38 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Testosterone | Testosterone | 38 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 14 |
| Naproxen | Naproxen | 33 | 13 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 20 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 27 |
| Ondansetron Odt | Ondansetron | 29 | 14 |
| Azithromycin | Azithromycin | 28 | 22 |
| Diclofenac Potassium | Diclofenac Potassium | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 12 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | 12 |
| Klor-Con M10 | Potassium Chloride | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Ramipril | Ramipril | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 11 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Primidone | Primidone | 22 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 12 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 17 |
| Digoxin | Digoxin | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Matzim La | Diltiazem Hcl | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Sulindac | Sulindac | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.50 · 4 records | Lilly USA, LLC | ABRYSVO, COMIRNATY, FREESTYLE LIBRE 3, MOUNJARO, PREVNAR 20, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error